Description: Ikonisys S.A., a cell based diagnostics company, engages in the design, manufacturing, marketing, and sale of medical diagnostic products for various cancers in the United States and Europe. It offers Ikoniscope Robotic Microscope that provides automated slide handling, slide scanning, and real-time image capture and analysis, and eliminates various factors that cause human error in testing; oncoFISH bladder that allows scanning and analysis of cells recovered from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; and oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of rearrangements of the gene encoding anaplastic lymphoma kinase (ALK). The company also provides oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer CS, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; Ikonisoft explorer tissue, a FISH scanning application for analysis of various tissue section hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems. Ikonisys S.A. is based in Paris, France.
Home Page: www.ikonisys.com
62 Rue De Caumartin
Paris,
75009
France
Phone:
33 39 348 901 9064
Officers
| Name | Title |
|---|---|
| Mr. Mario P. Crovetto | Chief Exec. Officer |
| Dr. Michael W. Kilpatrick Ph.D. | Founder & CSO |
| Mr. Alessandro Mauri | Chief Financial Officer |
| Mr. Bill Kochiss | Chief Technology Officer |
| Mr. Jurgen Schipper | Chief Commercial Officer |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7004 |
| Price-to-Sales TTM: | 28.1204 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |